Modern tendencies and concepts in treatment of knee osteoarthritis using hyaluronic acid drugs

Authors

  • Pavlo Bolkhovitin

DOI:

https://doi.org/10.15674/0030-59872015475-79

Keywords:

osteoarthritis, hyaluronic acid, knee joint

Abstract

Pharmacological treatment of knee osteoarthritis (OA) supposes to use drugs of symptomatic action (with immediate and prolonged effect) and structure-modifying action. Goal: to analyse modern concepts (visco-elastic protection and visco-analgesic effect) and modern tendencies (enlargement of molecular weight and concentration) in the using of hyaluronic acid (HA) agents to treat OA. Methods: information sources which provide the results of clinical investigation of HA using are studied. Results: in the concept of viscosupplementation the molecular weight and concentration of HA in normal synovial fluid are considered as
a reference standard. Exogenous intake of HA with high molecular weight and concentration increases the suspension properties of synovial fluid and prevent further degenerative changes in joint structures. In the concept of viscoanalgisation that also bases on the biomechanical properties of synovial fluid biological aspects are emphasized. Synolis VA became an innovation; it contents viscoelastic, sterile, apyretic, isotonic 2 % solution of sodium hyaluronate (molecular weight 2 000 000 Da) that placed in sorbitol matrix. Synolis VA is recommended to use under the conditions of knee OA on early stages (I–II according to Kellgren-Lawrence), when OA is accompanied by pain, despite other drug and drug-free therapy, with minor radiological signs; in case of OA with severe synovitis - anti-inflammatory therapy should be added (corticosteroids, NSAIDs and so on). There are some other indications: severe pain syndrome on the end-stages of knee OA (III–IV) in cases when joint replacements are contraindicated or patient refuse to perform it; alternative therapy, when NSAIDs are contraindicated, had some side-effects or no effect. Conclusion: the use of sodium hyaluronate cross-linked with sorbitol (Synolis VA) is prospective to treat all the stages of OA due to intense analgesic effect.

References

  1. Guidelines for testing slow acting an disease modifying drugs in osteoarthritis / M. Lequesne, K. Brandt, N. Bellamy [et al.] // J. Rheumatol. — 1994. — Vol. 21, Suppl. 41. — P. 65–71.
  2. Recommendations for the registration of drugs in the treatment of osteoarthritis / Group for the Respect of Ethics and Excellence in Science (GREES): osteoarthritis section (M. Dougados, J. P. Devogelaer, M. Annefeldt [et al.] // Ann. Rheum. Dis. — 1996. — Vol. 55 (8). — P. 552–557, doi: 10.1136/ard.55.8.552.
  3. Design and conduct of clinical trials in patients with osteoar¬thritis: recommendations from a task force of the Osteoarthritis Research Society. Results from a workshop / R. D. Altman, K. Brandt, M. Hochberg [et al.] // Osteoarthritis Cartilage. — 1996. — Vol. 4 (4). — P. 217–243.
  4. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip and hand osteoar¬thritis: consensus development in OMERACT III / N. Bellamy, J. Kirwan, R. D. Altman [et al.] // J. Rheumatol. — 1997. — Vol. 24 (4). — P. 799–802.
  5. Desmarais M. H. Value of intra-articular injections in osteo¬arthritis / M. H. Desmarais // Ann. Rheum. Dis. — 1952. — Vol. 11 (4). — P. 277–281.
  6. Aviad A. D. The molecular weight of therapeutic hyaluronan (sodium hyaluronate): how significant is it? / A. D. Aviad, J. B. Houpt // J. Rheumatol. — 1994. — Vol. 21 (2). — P. 297–301.
  7. Abantangelo G. Hyaluronan: biological role and function in articular joints / G. Abantangelo, M. O’Regan // Eur. J. Rheu¬matol. Inflam. — 1995. — Vol. 15. — P. 9–16.
  8. George E. Intra-articular hyaluronan treatment for osteoarthri¬tis / E. George // Ann. Rheum. Dis. — 1998. — Vol. 57. — P. 637–640, doi:10.1136/ard.57.11.637.
  9. Brandt K. D. Intraartricular injections of hyaluronan as treatment for knee osteoarthritis: what is the evidence? / K. D. Brandt, G. N. Smith, L. S. Simon // Arthritis Rheum. — 2000. — Vol. 43. — P. 1192–1203, doi: 10.1002/1529-0131(200006)43:6<1192::AID-ANR2>3.0.CO;2-L.
  10. Adams M. E. A risk-benefit assessment of injections of hyal¬uronan and it’s derivates in the treatment of osteoarthritis of the knee / M. E. Adams, A. J. Lussier, J. G. Peyron // Drug Saf. — 2000. — Vol. 23 (2). — P. 115–130, doi:10.2165/00002018-200023020-00003.
  11. Balazs E. A. Viscosupplementation: a new concept in the treatment of osteoarthritis / E. A. Balazs, J. L. Denlinger // J. Rheumatol. — 1993. — Vol. 20, Suppl. 39. — P. 3–9.
  12. Waddell D. D. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic im¬plications / D. D. Waddell // Drugs Aging. — 2007. — Vol. 24. 79 ISSN 0030-5987. Ортопедия, травматология и протезирование. 2015. № 4
  13. — P. 629–642, doi: 10.2165/00002512-200724080-00002.
  14. Recommendations for the medical management of osteo¬arthritis of the hip and knee: 2000 update/ R. D. Altman, M. C. Hochberg, R. W. Moskowitz [et al.] // Arthritis Rheum. — 2000. — Vol. 43 (9). — P. 1905–1915.
  15. EULAR recommendations for the management of knee os¬teoarthritis: report of a task force of the standing committee for international clinical studies including therapeutic trials (ESCISIT) / R. Pendleton, N. Arden, M. Dougados [et al.] // Ann. Rheum. Dis. — 2000. — Vol. 59. — P. 936–944, doi: 10.1136/ard.59.12.936.
  16. Rydell N. W. Effect of intra-articular injection of hyaluronic acid on the clinical symptoms of osteoarthritis and on granu¬lation tissue formation / N. W. Rydell, E. A. Balasz // Clin. Orthop. — 1971. — Vol. 80. — P. 25–32.
  17. Peyron J. G. Preliminary clinical assessment of Na-hyaluronate injection into human arthritic joint / J. G. Peyron, E. A. Balasz // Pathol. Biol. — 1974. — Vol. 22. — P. 731–736.
  18. Clinical studies of the intraarticular injections of Hyalon® (so¬dium hyaluronate) in the treatment of osteoarthritis of human knees / C. Weiss, E. A. Balasz, R. St Onge, J. L. Denlinger // Semin Arthritis Rheum. — 1981. — Vol. 11, Suppl. 1. — P. 143–144.
  19. Peyron J. G. Intra-articular hyaluronan injections in the treat¬ment of osteoarthritis: state-of-the-art review / J. G. Peyron // J. Rheumatol. — 1993. — Vol. 20, Suppl. 39. — P. 10–15.
  20. Maheu E. Sel sodique de l’acide hyaluronique (hyaluronan) et gonarthrose / E. Maheu, J. Lamotte, M. Lequesne // L’actualité rhumatologique / S. DeSèze, A. Ryckewaert, M. F. Kahn [et al.]. — Paris, Expansion Scientifique Française: 1994. — P. 324–339. 20. Viscosupplementation with hylan for the treatment of osteoar¬thritis: findings from clinical practice in Canada / A. Lussier, A. A. Cividino, C. A. McFarlane [et al.] // J. Rheumatol. — 1996. — Vol. 23. — P. 1579–1585.
  21. Longitudinal radiologic evaluation of osteoarthritis of the knee / M. Dougados, A. Gueguen, M. Nguyen [et al.] // J. Rheumatol. — 1992. — Vol. 19. — P. 378–384.
  22. Grecomoro G. Therapeutic synergism between hyaluronic acid and dexamethasone in the intra-articular treatment of osteoar¬thritis of the knee: a preliminary open study / G. Grecomoro, F. Piccione, G. Letizia // Curr. Med. Res. Opin. — 1992. — Vol. 13. — P. 49–55.
  23. The effects of hyaluronic acid on articular chondrocytes / M. Akmal, A. Singh, A. Anand [et al.] // J. Bone Joint Surg. Br. — 2005. — Vol. 87-B. — P. 1143–1149.
  24. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study / T. Conrozier, J. C. Balblanc, P. Richette [et al.] // J. Orthop. Res. — 2012. — Vol. 30 (5). — P. 679–685, doi: 10.1002/jor.21580.
  25. Moreland L. W. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: mechanisms of action / L. W. Moreland // Arthritis Res. Ther. — 2003. — Vol. 5. — P. 54–67.
  26. Heisel J. Safety and efficacy findings from a non-interventional study of a new hyaluronic acid/sorbitol formulation (GO-ON(R) matrix) for intra-articular injection to relieve pain and disability in osteoarthritis patients / J. Heisel, C. Kipshoven // Drug Res. (Stuttg.). — 2013. — Vol. 63 (9). — P. 445–449, doi: 10.1055/s-0033-1343425.
  27. Bausani M. Assessing the efficacy of a viscosupplement com¬bining hyaluronic acid and sorbitol (Synolis-VA) in patients with high grades knee osteoarthritis for whom corticotherapy is contraindicated / M. Bausani // Osteoarthritis Cartilage. — 2013. — Vol. 21. — Article S270, doi: 10.1016/j.joca.2013.02.564.
  28. Orlyanskiy B. Manual knee arthroscopy / V. Orlyanskiy, M. L. Golovakha. — Dnipropetrovs'k: Thresholds, 2007. — 149 p.

Downloads

How to Cite

Bolkhovitin, P. (2015). Modern tendencies and concepts in treatment of knee osteoarthritis using hyaluronic acid drugs. ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS, (4), 75–79. https://doi.org/10.15674/0030-59872015475-79

Issue

No. 4 (2015)

Section

ORIGINAL ARTICLES

License

Copyright (c) 2015 Pavlo Bolkhovitin

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.

Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.

The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).